

Sarborg Files U.S. Provisional Patent Application for its AI Signature Agent

WILMINGTON, De – March 05, 2026 -- Sarborg Limited (“**Sarborg**” or the “**Company**”), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“**USPTO**”) in relation to its proprietary AI Signature Agent.

The provisional patent application was filed on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801 by the USPTO.

The filing relates to Sarborg’s Signature Agent architecture, including its structured methodology for encoding, analysing and matching biological, chemical and industrial signatures to generate ranked, intelligence-driven outputs. The application represents a further step in formalising and protecting the Company’s intellectual property as it expands deployment of the Signature Agent across new therapeutic areas and additional sectors.

Sarborg’s Signature Agent was initially developed within the pharmaceutical sector, where it enables rapid drug–disease signature matching in minutes, a marked acceleration compared to traditional discovery and preclinical workflows that commonly span several years. The Company has since expanded the scope of its signature databases beyond pharmaceuticals into bacteria, agrochemicals and other structured domains.

The filing of this provisional patent application reflects continued momentum in Sarborg’s intellectual property strategy and reinforces the Company’s position as a signature-based intelligence business operating across multiple industries. Sarborg intends to continue building and protecting its proprietary methodologies as it advances commercial discussions and expands into additional therapeutic and industrial areas.

About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com